Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Receivables: 2010-2024

Historic Change in Receivables for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $197,708.

  • China Pharma Holdings' Change in Receivables fell 29.77% to $117,491 in Q3 2025 from the same period last year, while for Sep 2025 it was $515,669, marking a year-over-year increase of 47.75%. This contributed to the annual value of $197,708 for FY2024, which is 78.92% down from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' Change in Receivables is $197,708, which was down 78.92% from $938,021 recorded in FY2023.
  • China Pharma Holdings' 5-year Change in Receivables high stood at $938,021 for FY2023, and its period low was $170,194 during FY2022.
  • Its 3-year average for Change in Receivables is $435,308, with a median of $197,708 in 2024.
  • In the last 5 years, China Pharma Holdings' Change in Receivables spiked by 451.15% in 2023 and then tumbled by 78.92% in 2024.
  • Yearly analysis of 5 years shows China Pharma Holdings' Change in Receivables stood at $613,678 in 2020, then dropped by 11.10% to $545,534 in 2021, then slumped by 68.80% to $170,194 in 2022, then surged by 451.15% to $938,021 in 2023, then tumbled by 78.92% to $197,708 in 2024.